verupharma.com Open in urlscan Pro
151.101.194.159  Public Scan

Form analysis
1 forms found in the DOM

GET https://verupharma.com/

<form role="search" class="searchform fusion-search-form  fusion-search-form-classic" method="get" action="https://verupharma.com/">
  <div class="fusion-search-form-content">
    <div class="fusion-search-field search-field">
      <label><span class="screen-reader-text">Search for:</span>
        <input type="search" value="" name="s" class="s" placeholder="Search..." required="" aria-required="true" aria-label="Search...">
      </label>
    </div>
    <div class="fusion-search-button search-button">
      <input type="submit" class="fusion-search-submit searchsubmit" aria-label="Search" value="">
    </div>
  </div>
</form>

Text Content

Skip to content
 * Home
 * About
   * About Veru
   * Company Description
   * Management Team
   * Board of Directors
 * Pipeline
   * Sabizabulin for COVID-19
   * Enobosarm for Breast Cancer
   * Sabizabulin for Breast Cancer
   * Enobosarm + Abemaciclib Combination Therapy for Breast Cancer
   * Sabizabulin + Enobosarm Combination Therapy for Triple Negative Breast
     Cancer
   * Sabizabulin (VERU-111) for Prostate Cancer
   * VERU-100 for Prostate Cancer
   * Zuclomiphene Citrate for Hot Flashes
 * Urev – Sexual Health Division
   * Urev – Sexual Health Division
   * FC2 (US)
   * FC2 (International)
   * ENTADFI™
 * Investors
   * Investors
   * Press Releases
   * Stock Information
   * Financial Information
     * SEC Filings
     * Annual Reports
     * IRS Form 8937
   * Investor Presentations
   * Corporate Governance
     * Letter to Shareholders
     * Board Committees
     * Governance Documents
   * Investor Kit
 * News
 * Contact
 * Search for:
   


 * Home
 * About
   * About Veru
   * Company Description
   * Management Team
   * Board of Directors
 * Pipeline
   * Sabizabulin for COVID-19
   * Enobosarm for Breast Cancer
   * Sabizabulin for Breast Cancer
   * Enobosarm + Abemaciclib Combination Therapy for Breast Cancer
   * Sabizabulin + Enobosarm Combination Therapy for Triple Negative Breast
     Cancer
   * Sabizabulin (VERU-111) for Prostate Cancer
   * VERU-100 for Prostate Cancer
   * Zuclomiphene Citrate for Hot Flashes
 * Urev – Sexual Health Division
   * Urev – Sexual Health Division
   * FC2 (US)
   * FC2 (International)
   * ENTADFI™
 * Investors
   * Investors
   * Press Releases
   * Stock Information
   * Financial Information
     * SEC Filings
     * Annual Reports
     * IRS Form 8937
   * Investor Presentations
   * Corporate Governance
     * Letter to Shareholders
     * Board Committees
     * Governance Documents
   * Investor Kit
 * News
 * Contact




BIOPHARMACEUTICAL COMPANY FOCUSED IN INFECTIOUS DISEASES AND ONCOLOGY

Click to scroll



WE’RE







Veru is a biopharmaceutical company focused on developing novel medicines for
COVID-19 and other viral and ARDS-related diseases and for the management of
breast and prostate cancers




LATEST NEWS




FY 2022 Q3 EARNINGS CONFERENCE CALL

August 11, 2022 | 8am ET




Join Us





JEFFERIES GLOBAL HEALTHCARE CONFERENCE

June 8, 2022




Watch Replay




View Slide Deck





Listen to other presentations and conference calls



 * Jul 28, 2022
   
   Veru to Report Fiscal 2022 Third Quarter Financial Results, Host Conference
   Call on August 11th

 * Jul 27, 2022
   
   European Medicines Agency’s Emergency Task Force Has Initiated the Review of
   Veru’s Sabizabulin Treatment for Hospitalized COVID-19 Patients for Emergency
   Use in European Union Countries

 * Jul 25, 2022
   
   UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Supports
   Expedited Review of Marketing Authorization Application for Sabizabulin
   Treatment in Hospitalized COVID-19 Patients





MORE NEWS



VERU PIPELINE




SABIZABULIN FOR COVID-19


SABIZABULIN FOR COVID-19




Sabizabulin for the treatment of hospitalized patients with moderate to severe
COVID-19 infection



LEARN MORE


ENOBOSARM FOR BREAST CANCER


ENOBOSARM FOR BREAST CANCER




Enobosarm monotherapy for 3rd line treatment of AR+ER+HER2- metastatic breast
cancer



LEARN MORE


SABIZABULIN FOR BREAST CANCER


SABIZABULIN FOR BREAST CANCER




Sabizabulin monotherapy for 3rd line treatment of AR+ER+HER2- metastatic breast
cancer



LEARN MORE


ENOBOSARM + ABEMACICLIB COMBINATION THERAPY FOR BREAST CANCER


ENOBOSARM + ABEMACICLIB COMBINATION THERAPY FOR BREAST CANCER




Enobosarm + Abemaciclib Combination for treatment of 2nd line AR+ER+HER2-
metastatic breast cancer



LEARN MORE


SABIZABULIN + ENOBOSARM COMBINATION THERAPY FOR TNBC


SABIZABULIN + ENOBOSARM COMBINATION THERAPY FOR TNBC




Sabizabulin + Enobosarm Combination for 3rd line treatment of metastatic triple
negative breast cancer



LEARN MORE


SABIZABULIN FOR PROSTATE CANCER


SABIZABULIN FOR PROSTATE CANCER




Sabizabulin for treatment of metastatic castration resistant prostate cancer



LEARN MORE


VERU-100 FOR PROSTATE CANCER


VERU-100 FOR PROSTATE CANCER




VERU-100 for treatment of advanced hormone sensitive prostate cancer



LEARN MORE


ZUCLOMIPHENE CITRATE FOR HOT FLASHES


ZUCLOMIPHENE CITRATE FOR HOT FLASHES




Zuclomiphene Citrate for treatment of hot flashes, a side effect of androgen
deprivation therapy for prostate cancer



LEARN MORE




ABOUT VERU




ABOUT




PIPELINE




INVESTORS



MIAMI  |  LONDON  |  MALAYSIA

Sign Up for Investor Alerts


© 2022 Veru Inc. | All Rights Reserved | Accreditation and Certificates |
Privacy Policy | Anti-Trafficking Policy | Terms of Use | Contact Us
Website Design by Get Sharp, Inc.




Page load link

After submission, please check your email for our opt-in notice to complete your
sign-up.

X
Go to Top